Compare Amphastar Pharmaceuticals Inc (AMPH) vs Meta Platforms Inc (META) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Meta Platforms (META) trades at $669.21, up 5.97% in the last 24 hours, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $201B and net income of $60.5B, maintaining high profitability margins. Recent catalysts include the launch of Muse Spark AI model and consistent earnings beats, with Q1 2026 EPS of $7.31 exceeding expectations of $6.70.

Outlook remains positive with analyst consensus price target of $820.94 representing 22.7% upside potential. Key risks include ongoing regulatory litigation and high capital expenditures for AI infrastructure. The stock trades at reasonable valuations with P/E of 24.33 and P/S of 7.99, supported by strong institutional ownership and 79% buy ratings from analysts.